贝-拉帕通过与AKT1的相互作用抑制子宫癌的致癌
1Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Yanji, China.
Frontiers in pharmacology
|March 7, 2025
概括
贝塔-拉帕是一种天然化合物,通过向AKT1.1,有效地抑制子宫癌的进展. 这种抗瘤剂调节NQO1-过度表达细胞中的葡萄糖代谢和上皮-介质酶过渡 (EMT).
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 宫癌 (CC) 是一种普遍存在的恶性瘤,由于药物耐药性和复发,预后不佳.
- 贝塔-拉帕是一种天然子化合物,具有已证明的抗瘤特性,特别针对NQO1.
研究的目的:
- 研究β-拉帕对宫癌细胞代谢,增殖,转移,血管生成和上皮-介质细胞过渡 (EMT) 的影响.
- 为了确定参与β-lapachone抗癌活性的分子标和途径.
主要方法:
- 用β-拉帕进行宫癌细胞的体外治疗.
- 网络药理学和分子对接用于目标和途径识别.
- 基格路径丰富分析.
- 在体内验证使用裸体老鼠异种移植模型.
主要成果:
- 贝塔-拉帕显著抑制了高NQO1细胞中的CC细胞增殖和转移.
- 关键机制包括调节葡萄糖代谢,降低血管生成,并抑制EMT.
- 确定PI3K/AKT/mTOR通路的失活是关键机制.
- AKT1成为β-拉帕的潜在直接标.
结论:
- 贝塔-拉帕通过向AKT1.1,对宫癌产生强大的抗癌作用.
- 这种作用调节NQO1-过度表达细胞中的葡萄糖代谢和EMT.
- 这些发现为开发用于宫癌的基于β-lapachone的新疗法提供了基础.
更多相关视频
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.4K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
The Intrinsic Apoptotic Pathway
5.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.9K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Positive Regulator Molecules
105.6K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.6K
